Search results

Selected filters:

Life Sciences
Analysis

Article type

Topic

Sector

Regions

Year

240 results found for your search

Sort options
23 August 2019

Canon’s portfolio might be shrinking but it’s still world class    

Analysis shows that the Japanese company has cut down its filing activity and ramped up its abandonment rate, while there has been a recent litigation spike, too

23 August 2019

The latest 101 proposal is being held under lock and key but details are leaking out

Sources IAM has spoken to talk of a lengthening document that reflects the scale of the task ahead, while concern remains that a Section 112 problem is in danger of emerging

22 August 2019

Too often Unicorns lack meaningful IP protection and that makes them vulnerable to attack

A billion dollar valuation is all well and good, but many stellar start-ups risk being burned by having to pay-out big money to fend off patent infringement suits

21 August 2019

New written description rule set out by Federal Circuit in precedential Contrave judgment

Appellate court’s decision to uphold patent on weight loss treatment seems to create more flexible requirements.

19 August 2019

For high-cost, high-value patents, fixed-fee procurement could be the answer

A subscription model to cover the application process may well be the best way to make increased expenditure on securing portfolio-enhancing rights more palatable

16 August 2019

AstraZeneca faces increasingly tough evergreening battle in India

A recent Delhi court decision is a reminder of the tight restrictions around species and follow-on patents in the country

15 August 2019

Why the future of patent pools is a case of "it depends"

There are circumstances under which the model can definitely work, but these may not apply to all industries and might mean licensors having to modify their financial expectations

13 August 2019

CAFC closes off another defence against <em>inter partes </em>review

IPR cancellations of pre-AIA rights are not unconstitutional takings under Fifth Amendment, Federal Circuit rules

08 August 2019

Key pharma and agrochemical patents under threat in Brazil after court ruling

Owners face having the terms of their so-called mailbox rights reduced after decision overturns rules designed to counter chronic applications backlog at the country’s IP office

06 August 2019

Record-breaking pharma M&A value disguises plummeting deal-making activity

Abundant biotech funding seems to be empowering small- and medium-sized IP rights holders and driving down acquisition and licensing volume

06 August 2019

Canadian IP initiative aims to kick-start a revolution

Although it is home to many big ticket patent players, Canada has lagged in encouraging SMEs to maximise the value of the rights they own; new programme designed to reverse that trend

05 August 2019

China seeks to boost IP lending

Companies staked patents and trademarks to borrow $8.5 billion in the first half of 2019. CNIPA and China’s banking regulator want that figure to increase as SMEs face a credit squeeze

05 August 2019

CAFC creates blueprint for early stage challenges to claims brought under doctrine of equivalents

Amgen’s infringement suit was barred by prosecution history estoppel as the Federal Circuit affirmed district court’s Rule 12(b)(6) dismissal

01 August 2019

Expect Pfizer set to focus on more oncology opportunities following off-patent drug purge

After $12 billion Upjohn deal with Mylan, CEO Bourla says company is on the hunt for early- and mid-stage cancer assets

30 July 2019

Indian messaging app leads hike in domestic patent filings

Annual figures released by the country’s patent office also showed that it rapidly ramped up its ability to process examinations